Saatci Ali Osman, Ayhan Ziya, Engin Durmaz Ceren, Takes Omer
Department of Ophthalmology, Dokuz Eylul University, Izmir, Turkey.
Case Rep Ophthalmol. 2015 Dec 1;6(3):408-14. doi: 10.1159/000442346. eCollection 2015 Sep-Dec.
Intravitreal anti-vascular endothelial growth factor (VEGF) agents seem to be effective in choroidal neovascular membranes (CNV) in association with various entities of posterior uveitis. We herein report a 46-year-old woman who was treated with a simultaneous single intravitreal dexamethasone implant and ranibizumab administration for the treatment of unilateral extrafoveal CNV associated with an active serpiginous choroiditis. Simultaneously with the intravitreal therapy, oral mycophenolic acid (2 × 720 mg) was started, and oral cyclosporine (3 × 100 mg) was then added 2 months later. On the other hand, the fellow eye had been treated for subfoveal CNV but with an inactive disease 4 years previously and ended up with a final visual acuity of counting fingers despite treatment with a single session of photodynamic therapy and 3 subsequent intravitreal ranibizumab injections. Simultaneous administration of anti-VEGF agents and a dexamethasone implant can be a viable approach in eyes with CNV and active serpiginous choroiditis.
玻璃体内抗血管内皮生长因子（VEGF）药物似乎对与各种后葡萄膜炎相关的脉络膜新生血管膜（CNV）有效。我们在此报告一名46岁女性，她接受了玻璃体内同时植入地塞米松单剂量制剂和注射雷珠单抗，以治疗与活动性匐行性脉络膜炎相关的单侧黄斑外CNV。在进行玻璃体内治疗的同时，开始口服霉酚酸（2×720毫克），2个月后加用口服环孢素（3×100毫克）。另一方面，对侧眼曾因黄斑下CNV接受治疗，但4年前病情不活动，尽管接受了单次光动力疗法和随后3次玻璃体内注射雷珠单抗治疗，最终视力仍为指数。对于患有CNV和活动性匐行性脉络膜炎的眼睛，同时给予抗VEGF药物和地塞米松植入剂可能是一种可行的方法。
